Vitamin A and retinoid derivatives for lung cancer: A systematic review and meta analysis

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Fritz, Heidi ^a   Kennedy, Deborah ^a,b   Fergusson, Dean ^c   Fernandes, Rochelle ^a,b   Doucette, Steve ^c   Cooley, Kieran ^a,b   Seely, Andrew ^c   Sagar, Stephen ^d   Wong, Raimond ^d   Seely, Dugald ^a,c  

^a CANADIAN COLLEGE OF NATUROPATHIC MEDICINE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTHRENE; ALITRETINOIN; ALPHA INTERFERON; BETA CAROTENE; BEXAROTENE; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; DRUG METABOLITE; ETOPOSIDE; ETRETIN; ETRETINATE; FENRETINIDE; FLUOROURACIL; GEMCITABINE; INTERFERON; INTERLEUKIN 2; ISOTRETINOIN; MITOMYCIN C; NAVELBINE; PACLITAXEL; RETINOIC ACID; RETINOID; RETINOID DERIVATIVE; RETINOL; RETINOL PALMITATE; TEGRISON; UNCLASSIFIED DRUG; VINDESINE; DRUG DERIVATIVE;

ACNE VULGARIS; AREA UNDER THE CURVE; BREAST CANCER; CANCER MORTALITY; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CHEMORADIOTHERAPY; CLINICAL STUDY; CONFUSION; DATA BASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG USE; EVENT FREE SURVIVAL; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; KAPOSI SARCOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS; MUCOSAL DISEASE; MYALGIA; NIGHT BLINDNESS; OBSERVATIONAL STUDY; PRIMARY PREVENTION; PRIMARY TUMOR; PROMYELOCYTIC LEUKEMIA; PSORIASIS; REVIEW; SECONDARY PREVENTION; SKIN DISEASE; SKIN LYMPHOMA; SURVIVAL TIME; SYSTEMATIC REVIEW; T CELL LYMPHOMA; ANIMAL; LUNG TUMOR; METABOLISM;

ANIMALS; BETA CAROTENE; HUMANS; LUNG NEOPLASMS; RETINOIDS; VITAMIN A;

EID: 79959597795     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021107     Document Type: Review

References (99)

1. Alberg AJ, Brock MV, Samet JM, (2005) Epidemiology of lung cancer: looking to the future. J Clin Oncol 23: 3175-3185.
2. American Cancer Society (2010) Cancer reference information. What are the key statistics about lung cancer? www.cancer.org. Accessed 9 Debember 2010.
3. Colditz GA, Stampfer MJ, Willett WC, (1987) Diet and lung cancer. A review of the epidemiologic evidence in humans. Arch Intern Med 147: 157-160.
4. Goodman GE, Alberts DS, Meyskens FL, (2008) Retinol, vitamins, and cancer prevention: 25 Years of learning and relearning. J Clin Oncol 26: 5495-5496.
5. Meyskens JFL, Gilmartin E, Chase E, (1981) A broad phase II trial of 13-cis-retinoic acid in advanced cancer. Proc Am Assoc Cancer Res 22: C-151.
6. Micksche M, Cerni C, Kokron O, titscher R, Wrba H, (1977) Stimulation of immune response in lung cancer patients by vitamin A therapy. Oncology 34: 234-238.
7. Wolf G, (1996) A history of vitamin A and retinoids. FASEB J 10: 1102-1107.
8. Nettesheim P, Cone MV, Snyder C, (1976) The influence of retinyl acetate on the postinitiation phase of preneoplastic lung nodules in rats. Cancer Res 36: 966-1002.
9. Olsson L, Behnke O, Sorensen HR, (1985) Modulatory effects of 5-azacytidine, phorbol ester, and retinoic acid on the malignant phenotype of human lung cancer cells. Int J Cancer 35: 189-98.
10. Wilkoff LJ, Dulmadge EA, Chopra DP, (1980) Viability of cultured Lewis lung cell populations exposed to beta retinoic acid. Proc Soc Exp Biol Med 163: 233-236.
11. Nettesheim P, Williams ML, (1976) The influence of vitamin A on the susceptibility of the rat lung to 3-methylcholanthrene. Int J Cancer 17: 351-357.
12. Freemantle SF, Dragnev KH, Dmitrovsky E, (2006) The retinoic acid paradox in cancer chemoprevention. J Natl Cancer Inst 98: 426-427.
13. Micke O, Buntzel J, Kisters K, Schafer U, Micke P, et al. (2010) Complementary and alternative medicine in lung cancer patients: A neglected phenomenon? Front Radiat Ther Oncol 42: 198-205.
14. Higdon J, (2009) Vitamin A Linus Pauling Institute, Oregon State University Available: http://lpi.oregonstate.edu/infocenter/vitamins/vitaminA. Accessed 15 March 2010.
15. Van De, Kulier R, Gulmezoglu AM, Villar J, (2002) Vitamin A supplementation during rpegnancy. Cochrane Database Syst Rev CD001996.
16. Freemantle SJ, Spinella MJ, Dmitrovsky E, (2003) Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene 22: 7305-7315.
17. O'Neil C, Shevill E, Chang AB, (2008) Vitamin A supplementation for cystic fibrosis. Cochrane Database Syst Rev CD006751.
18. Tang G, (2010) Bioconversion of dietary provitamin A carotenoids to vitamin A in humans. Am J Clin Nutr 91: 1468S-1473S.
19. Stahl W, Sies H, (2005) Bioactivity and protective effects of natural carotenoids. Biochim Biophys Acta 1740: 101-107.
20. Higdon J, Drake V, (2009) Carotenoids: alpha-carotene, beta-carotene, beta-cryptoxanthin, lycopene, lutein, and zeaxanthin. Linus Pauling Institute, Oregon State University Available: http://lpioregonstateedu/infocenter/pytochemicals/carotenoids. Accessed 15 March 2010.
21. Parker RS, (1996) Absorption, metabolism, and transport of carotenoids. FASEB J 10: 542-551.
22. Black HS 92004) Pro-carcinogenic activity of beta carotene, a putative photoprotectant. Photochem Photobiol Sci 3: 753-758.
23. Bertram JS, Vine AL, (2005) Cancer prevention by retinoids and carotenoids: independent action on a common target. Biochim Biophys Acta 1740: 170-178.
24. No authors, (1982) Nomenclature of retinoids. Recommendations 1981. Eur J Biochem 129: 1-5.
25. Clarke N, Germain P, Altucci L, Gronemeyer H, (2004) Retinoids: potential in cancer prevention and therapy. Expert Rev Mol Med 6: 1-23.
26. Pilkington T, Brogden RN, (1992) Acitretin. A review of its pharmacology and therpeutic use. Drugs 43: 597-627.
27. Rigas JR, Dragnev KH, (2005) Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene. Oncologist 10: 22-23.
28. Dragnev KH, Petty WJ, Dmitrovsky E, (2003) Retinoid targets in cancer therapy and chemoprevention. Cancer Biol Ther 2: S150-156.
29. Fritsch PO, (1992) Retinoids in psoriasis and disorders of keratinization. J Am Acad Dermatol 27: S8-14.
30. Bollag W, Holdener EE, (1992) Retinoids in cancer prevention and therapy. Ann Oncol 3: 513-526.
31. Targretin (bexarotene). Eisai Inc. Available: www.Targretin.com Updated 2008. Accessed 16 March 2010.
32. Pasquali D, Rossi V, Bellastella G, Bellastella A, Sinisi AA, (2006) Natural and synthetic retinoids in prostate cancer. Curr Pharm Des 12: 1923-1929.
33. Dragnev KH, Petty WJ, Shah SJ, Lewis LD, Black Cc, et al. (2007) A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer. Clinical Cancer Research 13: 1794-1800.
34. Soria JC, Moon c, Wang L, Hittelman WN, Jang SJ, et al. (2001) Effects of N-(4-hydroxyphenyl)retinamide on hTERT expression in the bronchial epithelium of cigarette smokers. J Natl Cancer Inst 93: 1257-1263.
35. Gackowski D, Kowalewski J, Siomek A, Olinski R, (2005) Oxidative DNA damage and antioxidant vitamin level: comparison among lung cancer patients, healthy smokers and nonsmokers. Int J Cancer 114: 153-156.
36. Fu J, Ding Y, Huang D, Li H, Chen X, (2007) The retinoid X receptor-selective ligand, LGD1069, inhibits tumor-induced angiogenesis via suppression of VEGF in human non-small cell lung cancer. Cancer lett 248: 153-163.
37. Omenn GS, (2007) Chemoprevention of lung cancers: lessons from CARET, the beta-carotene and retinol efficacy trial, and prospects for the future. Eur J Cancer Prev 16: 184-191.
38. Hong WK, Endicott J, Itri LM, Doos W, Batsakis JG, et al. (1986) 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 315: 1501-1505.
39. Neely SM, Mehlmauer M, Feinstein DI, (1987) The effect of isotretinoin in six patients with cutaneous T-cell lymphoma. Arch Intern Med 147: 529-531.
40. Smith W, Saba N, (2005) Retinoids as chemoprevention for head and neck cancer: where do we go from here? Crit Rev Oncol Hematol 55: 143-52.
41. Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, et al. (1990) Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J med 323: 795-801.
42. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, et al. (92009) Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology study group. J Clin Oncol 27: 1007-1013.
43. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, et al. (1996) Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J med 334: 1150-1155.
44. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, et al. (2001) The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 134: 663-694.
45. Becker-Witt C, Weisshuhn TE, Ludtke R, Willich SN, (2003) Quality assessment of physical research in homeopathy. J Altern Complement Med (: 113-132.
46. Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, et al. (2006) Recommendatons of reporting randomized controlled trials of herbal interventions: explanation and elaboration. J Clin Epidemiol 59: 1134-1149.
47. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12.
48. Smith WE, Yazdi E, Miller L, (1972) Carcinogenesis in pulmonary epithelia in mice on different levels of vitamin A. Environ Res 5: 152-163.
49. Maeno T, Tanaka T, Sando Y, Suga T, Maeno Y, et al. (2002) Stimulation of vascular endothelial growth factor gene transcription by all trans retinoic acid through Sp1 and Sp3 sites in human bronchioloalveolar carcinoma cells. Am J Respir Cell Mol Biol 26: 246-253.
50. Mitsudomi T, Yatabe Y, (2010) Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FASEB J 277: 301-308.
51. Lonardo F, Rusch V, Langenfeld J, Dmitrovsky E, Klimstra DS, (1999) Overexpression of cyclins D1 and E is frequent in bronchial preneoplasia and precedes squamous cell carcinoma development. Cancer Res 59: 2470-2476.
52. Rusch V, Klimstra D, Linkov I, Dmitrovsky E, (1995) Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia and coexpression precedes squamous cell carcinoma development. Cancer Res 55: 1365-1372.
53. Ayoub J, Jean-Francois R, Cormier Y, Meyer D, Ying Y, et al. (1999) Placebo-controlled trial of 13-cis-retinoic acid activity on retinoic acid receptro-beta expression in a population at high risk: implications for chemoprevention of lung cancer. J clin Oncol 17: 3546-3552.
54. McLarty JW, Holiday DB, Girard WM, Yanagihara RH, Kummet TD, et al. (1995) Beta-carotene, vitamin A, and lung cancer chemoprevention: results of an intermediate endpoint study. Am J Clin Nutr 62: 1431S-1438S.
55. Kurie JM, Lee JS, Khuri FR, Mao L, Morice RC, et al. (2000) N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium. Clinical Cancer Research pp. 2973-2979.
56. Recchia F, Saggio G, Cesta A, Alesse E, Gallo R, et al. (2005) Phase II randomized study of interleukin-2 with or without 13-cis retinoic acid as maintenance therapy in patients with advanced cancer responsive to chemotherapy. Anticancer Res 25: 3149-3158.
57. Ramlau R, Zatloukal P, Jassem J, Schwarzenberger P, Orlov SV, et al. (2008) Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/ vinorelbine with cisplatin/vinorelbine in chemotherapy-naïve patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I. J Clin Oncol 26: 1886-1892.
58. Blumenschein GR, Khuri FR, Von Pawel J, Gatzemeier U, Miller WH, et al. (2008) Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy -naïve patients with advanced or metastatic non-small cell lung cancer: SPIRIT II. J Clin Oncol 26: 1879-1885.
59. Rizvi N, Hawkins MJ, Eisenberg PD, Yocum RC, Reich SD, (2001) Placebo-controlled trial of bexarotene, a retinoid X receptor agonist, as maintenance therapy for patients treated with chemotherapy for advanced non-small-cell lung cancer. Clinical Lung Cancer 2: 210-215.
60. Ruotsalainen T, Halme M, Isokangas OP, Pyrhönen S, Mäntylä M, et al. (2000) Interferon-alpha and 13-cis-retinoic acid as maintenance therapy after high-dose combination chemotherapy with growth factor support for small cell lung cancer - a feasibility study. Anti-Cancer Drugs 11: 101-108.
61. de Klerk NH, Musk AW, Ambrosini GL, Eccles JL, Hansen J, et al. (1998) Vitamin A and cancer prevention II: comparison of the effects of retinol and beta-carotene. Int J Cancer 75: 362-367.
62. Kamangar F, Qiao YL, Yu B, Sun XD, Abnet CC, et al. (2006) Lung cancer chemoprevention: a randomized, double-blind trial in Linxian, China. Cancer Epidemiol Biomarkers Prev 15: 1562-1564.
63. Lippman SM, Lee JJ, Karp DD, Vokes EE, Venner SE, et al. (2001) Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst 93: 605-617.
64. Pastorino U, Infante M, Maioli M, Chiesa G, Buyse M, et al. (1993) Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol 11: 1216-1222.
65. van Zandwijk N, Dalesio O, Pastorino U, de Vries N, van Tinteren H, (2000) EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst 92: 977-986.
66. Kalemkerian GP, Jiroutek M, Ettinger DS, Dorighi JA, Johnson DH, et al. (1998) A phase II study of all-trans-retinoic acid plus cisplatin and etoposide in patients with extensive stage small cell lung carcinoma: an Eastern Cooperative Oncology Group Study. Cancer 83: 1102-1108.
67. Dragnev KH, Petty WJ, Shah S, Biddle A, Desai NB, et al. (2005) Bexarotene and erlotinib for aerodigestive tract cancer. J Clin Oncol 23: 8757-8764.
68. Wildi JD, Baggstrom MQ, Suresh R, Read W, Fracasso PM, et al. (2008) A phase I study of docetaxel and bexarotene. Chemotherapy 54: 125-130.
69. Guarise A, Faccioli N, Ferrari M, Salvia R, Mucelli RP, et al. (92008) Evaluation of serial changes of pancreatic branch duct intraductal papillar mucinous neoplasms by follow-up with magnetic resonance imaging. Cancer Imaging 8: 220-228.
70. Danby FW, (2003) Night blindness, vitamin A deficiency, and isotretinoin psychotoxicity. Dermatol Online J 9: 30.
71. Khuri FR, Rigas JR, Figlin RA, Gralla RJ, Shin DM, et al. (2001) Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol 19: 2626-2637.
72. Ozpolat B, Lopez-Berestein G, Adamson P, Fu CHJ, Williams AH, (2003) Pharmacokinetics of intravenously administered liposomal all-trans-retinoic acid (atra) and orally administered atra in healthy volunteers. J Pharm Pharm Sci 6: 292-301.
73. Waladkhani AR, Clemens MR, (1997) Differences in the pharmacokinetics of 13-cis retinoic acid in cancer patients. Int J Cancer 70: 494-495.
74. DiPaola RS, Rafi MM, Vyas V, Toppmeyer D, Rubin E, et al. (1999) Phase I clinical and pharmacologic study of 13-cis-retinoic acid, interfon alfa, and paclitaxel in patients with prostate cancer and other advanced malignancies. J Clin Oncol 17: 2213-2218.
75. Tyagi P, Belani CP, Jain VK, (2005) Bexarotene in combination with chemotherapy fails to prolong survival in patients with advanced non-small-cell lung cancer: results from the SPIRIT I and II trials. Clin Lung Cancer 7: 17-19.
76. Witschi H, (2000) Successful and not so successful chemoprevention of tobacco smoke-induced lung tumors. Exp Lung Res 26: 743-755.
77. Witschi H, Uyeminami D, Moran D, Espiritu I, (2000) Chemoprevention of tobacco smoke lung carcinogenesis in mice after cessation of smoke exposure. Carcinogenesis 21: 977-982.
78. Meyskens FL Jr, Szabo E, (2005) Diet and cancer: the disconnect between epidemiology and randomized clinical trials. Cancer Epidemiol Biomarkers Prev 14: 1366-1369.
79. Ray A, (2005) Cancer preventive role of selected dietary factors. Indian J Cancer 42: 15-24.
80. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, et al. (1996) Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst 88: 1550-1559.
81. Goodman GE, Thornquist MD, Balmes J, Cullen MR, Meyskens FL Jr, et al. (2004) The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements. J Natl Cancer Inst 96: 1743-1750.
82. Redlich CA, Blaner WS, Van Bennekum AM, Chung JS, Clever SL, et al. (1998) Effect of supplementation with beta-carotene and vitamin A on lung nutrient levels. Cancer Epidemiol Biomarkers Prev 7: 211-214.
83. Goodman GE, Omenn GS, Thornquist MD, Lund B, Metch B, et al. (1993) The Carotene and Retinol Efficacy Trial (CARET) to prevent lung cancer in high-risk populations: pilot study with cigarette smokers. Cancer Epidemiol Biomarkers Prev 2: 389-396.
84. Albanes D, Heinonen OP, Taylor PR, Virtamo J, Edwards BK, et al. (1996) Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. J Natl Cancer Inst 88: 1560-1570.
85. Albanes D, Virtamo J, Taylor PR, Rautalahti M, Peitinen P, et al. (1997) Effects of supplemental beta-carotene, cigarette smoking, and alcohol consumption on serum carotenoids in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Am J Clin Nutr 66: 366-372.
86. van Helden YG, Keijer J, Heil SG, Pico C, Palou A, et al. (2009) Beta-carotene affects oxidative stress-related DNA damage in lung eipthelial cells and in ferret lung. Carcinogenesis 30: 2070-2076.
87. Wang XD, Liu C, Bronson RT, Smith DE, Kinsky NI, et al. (1999) Retinoid signaling and activator protein-1 expression in ferrets given beta-carotene supplements and exposed to tobacco smoke. J Natl Cancer Inst 91: 60-66.
88. Roehrs M, Valentini J, Bulcao R, Moreira JC, Biesalksi H, et al. (2009) The plasma retinol levels as pro-oxidant/ oxidant agents in haemodialysis patients. Nephrol Dial Transplant 24: 2212-2218.
89. Patrick L, (2000) Beta-carotene: the controversy continues. Altern Med Rev 5: 530-545.
90. Omenn GS, (1998) Chemoprevention of lung cancer: the rise and demise of beta-carotene. Annu Rev Public Health 19: 73-99.
91. Siems W, Sommerburg O, Schild L, Augustin W, Langhans CD, et al. (2002) Beta-carotene cleavage products induce oxidative stress in vitro by impairing mitochondrial respiration. FASEB J 16: 1289-1291.
92. Acin-Perez R, Hoyos B, Zhao F, Vinogradov V, Fischman DA, et al. (2010) Control of oxidative phosphorylation by vitamin A illuminates a fundamental role in mitochondrial energy homeostasis. FASEB J 24: 627-636.
93. Gallicchio L, Boyd K, Matanoski G, Tao XG, Chen L, et al. (2008) Carotenoids and the risk of developing lung cancer: a systematic review. Am J Clin Nutr 88: 372-383.
94. Virtamo J, Pietinen P, Huttunen JK, Korhonen P, Mahila N, et al. (2003) Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-up. JAMA 290: 476-485.
95. Cook NR, Le IM, Manson JE, Buring JE, Hennekens CH, (2000) Effects of beta-carotene supplementation on cancer incidence by baseline characteristics in the Physicians' Health Study (United States). Cancer Causes Contorl 11: 617-626.
96. Lee IM, Cook NR, Manson JE, Buring JE, Hennekens CH, (1999) Beta-carotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study. J Natl Cancer Inst 91: 2102-2106.
97. Gregory J, Feusner J, (2009) Acute promyelocytic leukemia in childhood. Curr Oncol Rep 11: 439-445.
98. Lippman SM, Basakis JG, Toth BB, Weber RS, Lee JJ, et al. (1993) Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med 328: 15-20.
99. Buntzel J, Kuttner K, (1998) Chemoprevention with interferon alfa and 13-cis retinoic acid in the adjunctive treatment of head and neck cancer. Auris Nasus Larynx 25: 413-418.